Skip to content

Clinical trials

Graft vs Host Disease trials in the United States with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Graft vs Host Disease Phase: Not applicable Country / region: United States Clear all

41 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20003
20013
20021
20032
20043
20053
20062
20101
20112
20121
20131
20143
20151
20172
20191
20201
20211
20223
20231
20251

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed17
Terminated13
Unknown status4
Active, not recruiting3
Recruiting3
Not yet recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Fairview University Medical Center3
Rutgers, The State University of New Jersey3
Children's Hospital Medical Center, Cincinnati2
Dana-Farber Cancer Institute2
Massachusetts General Hospital2
National Heart, Lung, and Blood Institute (NHLBI)2
Roswell Park Cancer Institute2
Vanderbilt-Ingram Cancer Center2
Ayman Saad1
Christopher Dvorak1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Graft vs Host Disease41
Multiple Myeloma10
Leukemia9
Myelodysplastic Syndromes9
Precursor Cell Lymphoblastic Leukemia-Lymphoma9
Congenital Abnormalities8
Hodgkin Disease8
Leukemia, Lymphocytic, Chronic, B-Cell8
Leukemia, Myeloid, Acute8
Burkitt Lymphoma7

Trials

Showing 1 to 25 of 41. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.